Cytokinetics Incorporated

33.70+0.6000+1.81%Vol 842.28K1Y Perf 44.14%
Sep 15th, 2021 16:00 DELAYED
BID33.68 ASK33.71
Open33.00 Previous Close33.10
Pre-Market- After-Market-
 - -%  - -
Target Price
47.00 
Analyst Rating
Strong Buy 1.10
Potential %
39.47 
Finscreener Ranking
★★★★     54.06
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     53.31
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     61.09
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
96.84 
Earnings Rating
Strong Sell
Market Cap2.81B 
Earnings Date
3rd Nov 2021
Alpha0.01 Standard Deviation0.17
Beta1.41 

Today's Price Range

32.4034.00

52W Range

14.7134.32

5 Year PE Ratio Range

-6.2050.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
12.15%
1 Month
8.15%
3 Months
54.66%
6 Months
41.12%
1 Year
44.14%
3 Years
302.15%
5 Years
290.05%
10 Years
319.15%

TickerPriceChg.Chg.%
CYTK33.700.60001.81
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Financial StrengthValueIndustryS&P 500US Markets
5.70
5.90
0.93
15.20
-3.70
Leverage Ratio 6.20
ProfitabilityValueIndustryS&P 500US Markets
-
-212.40
-208.70
-476.90
-
RevenueValueIndustryS&P 500US Markets
57.80M
0.69
34.06
1.58
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.65-0.86-32.31
Q01 2021-0.59-0.66-11.86
Q04 2020-0.48-0.62-29.17
Q03 2020-0.59-0.0591.53
Q02 2020-0.57-0.68-19.30
Q01 2020-0.50-0.66-32.00
Q04 2019-0.42-0.52-23.81
Q03 2019-0.56-0.5010.71
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.77-18.46Negative
12/2021 QR-0.79-16.18Negative
12/2021 FY-3.02-15.71Negative
12/2022 FY-3.17-7.46Negative
Next Report Date3rd Nov 2021
Estimated EPS Next Report-0.77
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume842.28K
Shares Outstanding83.51M
Shares Float70.99M
Trades Count11.48K
Dollar Volume11.81M
Avg. Volume1.23M
Avg. Weekly Volume1.17M
Avg. Monthly Volume895.89K
Avg. Quarterly Volume1.85M

Cytokinetics Incorporated (NASDAQ: CYTK) stock closed at 33.7 per share at the end of the most recent trading day (a 1.81% change compared to the prior day closing price) with a volume of 853.02K shares and market capitalization of 2.81B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 156 people. Cytokinetics Incorporated CEO is Robert I. Blum.

The one-year performance of Cytokinetics Incorporated stock is 44.14%, while year-to-date (YTD) performance is 62.18%. CYTK stock has a five-year performance of 290.05%. Its 52-week range is between 14.71 and 34.32, which gives CYTK stock a 52-week price range ratio of 96.84%

Cytokinetics Incorporated currently has a PE ratio of -13.40, a price-to-book (PB) ratio of 149.51, a price-to-sale (PS) ratio of 45.48, a price to cashflow ratio of 277.60, a PEG ratio of 2.32, a ROA of -38.48%, a ROC of -53.61% and a ROE of 472.68%. The company’s profit margin is -%, its EBITDA margin is -208.70%, and its revenue ttm is $57.80 Million , which makes it $0.69 revenue per share.

Of the last four earnings reports from Cytokinetics Incorporated, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.77 for the next earnings report. Cytokinetics Incorporated’s next earnings report date is 03rd Nov 2021.

The consensus rating of Wall Street analysts for Cytokinetics Incorporated is Strong Buy (1.1), with a target price of $47, which is +39.47% compared to the current price. The earnings rating for Cytokinetics Incorporated stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cytokinetics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cytokinetics Incorporated has a Buy technical analysis rating based on Technical Indicators (ADX : 8.65, ATR14 : 1.67, CCI20 : 108.92, Chaikin Money Flow : -0.05, MACD : 0.71, Money Flow Index : 55.16, ROC : 1.26, RSI : 62.06, STOCH (14,3) : 88.12, STOCH RSI : 1.00, UO : 51.64, Williams %R : -11.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cytokinetics Incorporated in the last 12-months were: B. Lynne Parshall (Option Excercise at a value of $211 698), B. Lynne Parshall (Sold 30 311 shares of value $909 330 ), Ching Jaw (Option Excercise at a value of $275 700), Ching Jaw (Sold 27 500 shares of value $825 000 ), David W. Cragg (Option Excercise at a value of $408 481), David W. Cragg (Sold 47 957 shares of value $1 233 203 ), Edward M. Kaye (Option Excercise at a value of $152 200), Edward M. Kaye (Sold 20 000 shares of value $600 000 ), Fady Ibraham Malik (Option Excercise at a value of $117 750), Fady Ibraham Malik (Sold 31 673 shares of value $688 331 ), John T. Henderson (Option Excercise at a value of $49 853), John T. Henderson (Sold 4 591 shares of value $112 259 ), Leonard Patrick Gage (Option Excercise at a value of $228 792), Leonard Patrick Gage (Sold 28 055 shares of value $625 878 ), Robert I. Blum (Option Excercise at a value of $1 581 657), Robert I. Blum (Sold 130 000 shares of value $2 876 105 ), Sandford Drexel Smith (Option Excercise at a value of $516 950), Sandford Drexel Smith (Sold 55 936 shares of value $1 489 825 ), Santo J. Costa (Option Excercise at a value of $141 750), Santo J. Costa (Sold 15 000 shares of value $450 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
3 (75.00 %)
Moderate Buy
1 (20.00 %)
1 (20.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.10
Strong Buy
1.10
Strong Buy
1.50

Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.

CEO: Robert I. Blum

Telephone: +1 650 624-3000

Address: 280 East Grand Avenue, South San Francisco 94080, CA, US

Number of employees: 156

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

100%0%

Bearish Bullish

59%41%

Bearish Bullish

46%54%

News

Stocktwits